Use of immuno-oncology

This module explains which types of cancer are treated with immuno-oncological treatments, and also discusses the side effects associated with new immuno-oncological agents.

1. Evan J. Lipson Charles G. Drake: Ipilimumab: an Anti-CTLA-4 Antibody for Metastatic Melanoma;  Clin. Cancer Res. 17, Nr. 22, 2011, S. 6958–62.

2. Ribas A et al; Efficacy and Safety of the anti-PD-1 monoclonal antibody mk-3475 in 411 patients with melanoma; J Clin Oncol 2014, 32 (18 Suppl 1): LBA9000

3. Robert C et al; Pembrolizumab versus Ipilimumab in Advanced Melanoma; N Engl J Med April 2015 (online first)

4. Rawyn M Poole et al; Pembrolizumab: First Global Approval; Drugs (2014) 74: 1973-1981

5. Amos S et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011. doi: 10.1182/blood-2011-01-325266.

6. Pardoll DM et al; The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012; 12(4): 252-65; doi: 10.1038/nrc3239

7. Patsoukis N et al; Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation; Science Signal (2012); Vol. 5, Issue 230, p. ra46.

Responsible for the content: © 2015 KWHC GmbH, Alewinstr. 13, 29525 Uelzen (Germany). The image sources can be found at:

Latest expert presentations

View more